Nuo Therapeutics Inc (AURX)
0.80
+0.05
(+6.67%)
USD |
OTCM |
Apr 18, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 33.85M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -72.88% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 69.02 |
| Price to Book Value | 46.58 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year. |
| URL | https://www.nuot.com |
| Investor Relations URL | N/A |
| HQ State/Province | Texas |
| Sector | |
| Industry | |
| Equity Style | N/A |
| Next Earnings Release | May. 15, 2024 (est.) |
| Last Earnings Release | Nov. 20, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The Aurix product became commercially available for sale in current financial year. |
| URL | https://www.nuot.com |
| Investor Relations URL | N/A |
| HQ State/Province | Texas |
| Sector | |
| Industry | |
| Equity Style | N/A |
| Next Earnings Release | May. 15, 2024 (est.) |
| Last Earnings Release | Nov. 20, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |